RT Journal Article
SR Electronic
T1 Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results
JF Canadian Journal of Surgery
JO CAN J SURG
FD Canadian Medical Association
SP 15
OP 20
DO 10.1503/cjs.011511
VO 56
IS 1
A1 Jennifer B. Keogh
A1 Anthony Brancatisano
A1 Sue F. Taylor
A1 Fiona McDonald
A1 Roy Brancatisano
A1 Jeffrey M. Hamdorf
A1 Jacob Chisholm
A1 Lillian Kow
A1 Sara Wahlroos
A1 Brendan Ryan
A1 Jim Toouli
YR 2013
UL http://canjsurg.ca/content/56/1/15.abstract
AB Background: The Swedish adjustable gastric band VC (SAGB-VC) has been in use in Australia since 2007. We evaluated its efficacy and safety.Methods: We retrospectively analyzed the prospective clinical data of patients who received the implant between November 2007 and June 2009 at 3 Australian bariatric centres.Results: In all, 1176 patients (mean age 45.9 [standard deviation (SD) 12.3] yr, mean body mass index 43.4 [SD 7.6]) received the SAGB-VC. At a mean follow-up of 11 (SD 3) months, weight reduced by a mean of 18.4 (SD 11.1) kg with an excess weight loss of 37.8% (SD 19.9%). Body mass index decreased (from mean 43.4 [SD 7.7] to mean 36.7 [SD 6.5], p < 0.001). Type 2 diabetes (T2DM) was reported in 167 patients and hypertension in 373. Improvement occurred in 73.5% of patients with T2DM and 31% with hypertension, with patient-reported reduction or cessation of medication. Metabolic syndrome indices improved during follow-up: high-density lipoprotein cholesterol (mean 1.3 [SD 0.3] v. mean 1.4 [SD 0.3] mmol/L, p < 0.001), triglycerides (mean 1.6 [SD 0.8] v. mean 1.3 [SD 0.7] mmol/L, p < 0.001), waist circumference (men 141 [SD 103] to 121 [SD 15] cm, women 117 [SD 14] to 105 [SD 14] cm, both p < 0.001), C-reactive protein (90.5 [SD 75.2] v. 53.3 [SD 61.9] nmol/L, p < 0.001). The complication rate was 4.2%.Conclusion: The SAGB-VC is safe and effective for treating obesity and its comorbidities. The results are reproducible in separate Australian centres and consistent with published literature.